Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure

Circulation

Volumn 100, Issue 19, 1999, Pages 2003-2009

  Houck, Ward V ^d   Pan, Lydia C ^a,b   Kribbs, Scott B ^d   Clair, Mark J ^d   McDaniel, George M ^d   Krombach, R Stephen ^d   Merritt, William M ^d   Pirie, Christine ^a,b   Iannini, Julie P ^d   Mukherjee, Rupak ^d   Spinale, Francis G ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d NONE

Author keywords

Contractility; Growth substances; Hormones; Ventricles

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); GROWTH HORMONE; GROWTH PROMOTOR; ISOPRENALINE; SOMATOMEDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE CONTRACTION; HEMODYNAMICS; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; STEADY STATE; SWINE;

EID: 0033539673     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.19.2003     Document Type: Article

References (28)

1. Yang R, Bunting S, Gillett N, Clark R, Hongkui J. Growth hormone improves cardiac performance in experimental heart failure. Circulation. 1995;92:262-267.
2. 2+ handling and enhance cardiac performance. Circ Res. 1996;79: 227-236.
3. Mayoux E, Ventura-Clapier R, Timsit J, Behar-Cohen F, Hoffman C, Mercadier JJ. Mechanical properties of rat cardiac skinned fibers are altered by chronic growth hormone hypersecretion. Circ Res. 1993;72: 57-64.
4. Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev. 1994;15:555-573.
5. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B, Sacca L. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996;334:809-814.
6. Sacca L, Fazio S. Cardiac performance: growth hormone enters the race. Nat Med. 1996;2:29-31.
7. Spinale FG, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Arnim AE, Powell JR, Koster WH. Angiotensin converting enzyme inhibition and the progression of congestive cardiomyopathy: effects on left ventricular and myocyte structure and function. Circulation. 1995;92: 562-568.
8. Tomita M, Spinale FG, Crawford FA, Zile MR. Changes in left ventricular volume, mass and function during development and regression of supraventricular tachycardia-induced cardiomyopathy: disparity between recovery of systolic vs diastolic function. Circulation. 1991;83:635-644.
9. Spinale FG, Tanaka R, Crawford FA, Zile MR. Changes in myocardial blood flow during the development and recovery from tachycardia-induced cardiomyopathy. Circulation. 1992;85:717-729.
10. Spinale FG, Fulbright BM, Mukherjee R, Tanaka R, Hu J, Crawford FA, Zile MR. Relationship between ventricular and myocyte function with tachycardia-induced cardiomyopathy. Circ Res. 1992;71:174-187.
11. Gaasch WH, Freeman GL. Functional properties of normal and failing hearts. In: McCall D, Ruhimtoola SH, eds. Heart Failure. New York, NY: Chapman & Hall; 1995:14-29.
12. Spinale FG, Zellner JL, Tomita M, Crawford FA, Zile MR. Relationship between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy. Circ Res. 1991;69:1058-1067.
13. Gerdes AM, Kellerman SE, Malec KB, Schocken DD. Transverse shape characteristics of cardiac myocytes from rats and humans. Cardioscience. 1994;5:31-36.
14. Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol. 1991;261: H308-H318.
15. Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Psival H, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation. 1995;92:778-784.
16. Klindt J, Yen JT, Buonomo FC, Roberts AJ, Wise T. Growth, body composition, and endocrine responses to chronic administration of insulin-like growth factor I and(or) porcine growth hormone in pigs. J Anim Sci. 1998;76:2368-2381.
17. Ito H, Hiro M, Hirata Y, Tsujino M, Adachi S, Shichiri M, Koike A, Nogami A, Marumo F. Insulin-like growth factor-1 induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation. 1993;87:1715-1721.
18. Eble DM, Walker JD, Mukherjee R, Samarel AM, Spinale FG. Myosin heavy chain synthesis is increased in a rabbit model of heart failure. Am J Physiol. 1997;272:H969-H978.
19. Young LH, Renfu Y, Hu X, Chong S, Hasan S, Jacob R, Sherwin RS. Insulin-like growth factor-1 stimulates cardiac myosin heavy chain and actin synthesis in the awake rat. Am J Physiol. 1999;276:E143-E150.
20. Kajstura J, Zhang X, Liu Y, Szoke E, Cheng W, Olivetti G, Hintze TH, Anversa P. The cellular basis of pacing-induced cardiomyopathy: myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation. 1995;92:2306-2317.
21. Timsit J, Riou B, Bertherat J, Wisnewsky C, Kato NS, Weisberg AS, Lubetzki J, Lecarpentier Y, Winegrad S, Mercadier JJ. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, myosin adenosine triphosphatase activity of the rat left ventricle. J Clin Invest. 1990;86:507-515.
22. Johannsson G, Bengtsson BA, Andersson B, Isgaard J, Caidahl K. Long term cardiovascular effects of growth hormone treatment in GH deficient adults: preliminary data in a small group of patients. Clin Endocrinol. 1996;45:305-314.
23. Moller J, Jorgensen JD, Frandsen E, Laursen T, Christiansen JS. Body fluids, circadian blood pressure and plasma renin during growth hormone administration: a placebo controlled study with two growth hormone doses in healthy adults. Scand J Clin Lab Invest. 1995;55:663-669.
24. Hu Y, Pete G, Walsh MF, Sowers J, Dunbar JC. Central IGF-1 decreases systemic blood pressure and increases blood flow in selective vascular beds. Horm Metab Res. 1996;29:211-214.
25. Sverrisdottir YB, Elam M, Herlitz H, Bengtsson BA, Johannsson G. Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. J Clin Endocrinol Metab. 1998; 83:1881-1885.
26. Pieske B, Kretschmann B, Meyer M, Holubarsch C, Weirich J, Posival H, Minami K, Just H, Hasenfuss G. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation. 1995;92:1169-1178.
27. Shen YT, Woltmann RF, Appleby S, Prahalda S, Krause SM, Kivilghn SD, Johnson RG, Siegl PK, Lynch JJ. Lack of beneficial effects of growth hormone treatment in conscious dogs during development of heart failure. Am J Physiol. 1998;274:H456-H466.
28. Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hanlein D, Willenbrock R, Anker SD, Poole-Wilson PA, Ranke MB, Dietz, R. Randomized, double-blind, placebo controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet. 1998;351:1233-1237.